{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:46:56Z","timestamp":1747198016552,"version":"3.40.5"},"reference-count":16,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2017-0264_s_999_w2aab3b7c17b1b6b1aab1c17b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>The objective of the study was to compare the diagnostic yield of home-made ELISA tests based on synthetic chimeric fibrin\/filaggrin citrullinated peptides (CFFCPs) with CCP3 and CCP3.1 commercial tests to detect anti-citrullinated protein\/peptide antibodies (ACPAs) in rheumatoid arthritis (RA) patients. The prognostic value is also studied in a cohort of patients with early RA. Moreover, we transfer immunological assays from microtiter plates to microarray formats to allow the simultaneous analysis of several peptide sequences and reduce the volume of serum from patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0264_s_998_w2aab3b7c17b1b6b1aab1c17b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>The diagnostic study includes: 100 RA patients who fulfilled the 1987 ACR criteria; 100 healthy blood donors; 35 patients with SLE according ACR criteria; 35 patients with PsA fulfilling the Wright and Moll criteria and 30 patients with HCV infection. The prognostic value study includes 50 patients with early RA with follow-up data available. All samples are from outpatients attending the Rheumatology Department of the Hospital Clinic of Barcelona.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0264_s_997_w2aab3b7c17b1b6b1aab1c17b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Similar sensitivity, specificity and predictive values for the diagnosis of RA of CCFCPs compared to CCP3\/CCP3.1 were obtained. Although a high concordance is observed between anti-CFFCPs and anti-CCP3\/CCP3.1 in the early patients that rendered Larsen radiographic progression, CFFCPs could be a better marker of radiographic outcome. Strong correlations between the microarray and ELISA results were found for individual CFFCPs peptides.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2017-0264_s_996_w2aab3b7c17b1b6b1aab1c17b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>The development of multiplexing techniques combining a different spectrum of markers in a single analysis, including CFFCP peptides, could allow a more detailed analysis of the autoantibodies reactivity found in the sera of patients suffering of this heterogeneous disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2017-0264","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T10:01:29Z","timestamp":1504000889000},"page":"285-293","source":"Crossref","is-referenced-by-count":5,"title":["Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3\/CCP3.1 assays"],"prefix":"10.1515","volume":"56","author":[{"given":"Mar\u00eda J.","family":"G\u00f3mara","sequence":"first","affiliation":[{"name":"Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Bleda","sequence":"additional","affiliation":[{"name":"Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan P.","family":"Salvador","sequence":"additional","affiliation":[{"name":"CIBER de Bioingenier\u00eda, Biomateriales y Nanomedicina (CIBER-BBN) , Barcelona , Spain"},{"name":"Nanobiotechnology for Diagnostics Group, IQAC-CSIC , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[{"name":"Unit of Arthritis, Hospital Cl\u00ednic , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8677-2340","authenticated-orcid":false,"given":"Isabel","family":"Haro","sequence":"additional","affiliation":[{"name":"Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC , Barcelona , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"2021021300551635636_j_cclm-2017-0264_ref_001_w2aab3b7c17b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Schellekens GA, de Jong BA, Van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273\u201381.","DOI":"10.1172\/JCI1316"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_002_w2aab3b7c17b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011;7:391\u20138.","DOI":"10.1038\/nrrheum.2011.76"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_003_w2aab3b7c17b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Wiik AS, van Venrooij WJ, Pruijn GJ. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 2010;1:90\u20133.","DOI":"10.1016\/j.autrev.2010.08.009"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_004_w2aab3b7c17b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012;12:318\u201322.","DOI":"10.1016\/j.autrev.2012.05.007"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_005_w2aab3b7c17b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Schellekens GA, Visser H, de Jong BA, Van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155\u201363.","DOI":"10.1002\/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_006_w2aab3b7c17b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008;27:77\u201383.","DOI":"10.1007\/s10067-007-0656-4"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_007_w2aab3b7c17b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Correia ML, Carvalho S, Fortuna J, Pereira MH. Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 2008;34:21\u20135.","DOI":"10.1007\/s12016-007-8030-5"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_008_w2aab3b7c17b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Swart A, Burlingame RW, G\u00fcrtler I, Mahler M. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis. Clin Chim Acta 2012;414:266\u201372.","DOI":"10.1016\/j.cca.2012.09.015"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_009_w2aab3b7c17b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Szekanecz Z, Szab\u00f3 Z, Zeher M, So\u00f3s L, Dank\u00f3 K, Horv\u00e1th I, et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res 2013;56:439\u201343.","DOI":"10.1007\/s12026-013-8425-8"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_010_w2aab3b7c17b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Uysal H, Nandakumar KS, Kessel C, Haag S, Carlsen S, Burkhardt H, et al. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 2010;233:9\u201333.","DOI":"10.1111\/j.0105-2896.2009.00853.x"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_011_w2aab3b7c17b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci 2011;108:17372\u20137.","DOI":"10.1073\/pnas.1114465108"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_012_w2aab3b7c17b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Darrah E, Andrade F. Citrullination, and carbamylation, and malondialdehyde-acetaldehyde! Oh My! Entering the forest of autoantigen modifications in rheumatoid arthritis. Arthritis Rheum 2015;67:604\u20138.","DOI":"10.1002\/art.38970"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_013_w2aab3b7c17b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Perez ML, Gomara MJ, Ercilla G, Sanmarti R, Haro I. Antibodies to citrullinated human fibrinogen synthetic peptides in diagnosing rheumatoid arthritis. J Med Chem 2007;50:3573\u201384.","DOI":"10.1021\/jm0701932"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_014_w2aab3b7c17b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Sanmarti R, Graell E, Perez ML, Ercilla G, Vinas O, Gomez-Puerta JA, et al. Diagnostic and prognostic value of antibodies against chimeric fibrin\/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. Arthritis Res Ther 2009;11:R135.","DOI":"10.1186\/ar2802"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_015_w2aab3b7c17b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837\u201345.","DOI":"10.2307\/2531595"},{"key":"2021021300551635636_j_cclm-2017-0264_ref_016_w2aab3b7c17b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L, et al. Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther 2012;14:R201.","DOI":"10.1186\/ar4039"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2018.56.issue-2\/cclm-2017-0264\/cclm-2017-0264.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0264\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:57:57Z","timestamp":1619049477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2017-0264\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,8,29]]},"published-print":{"date-parts":[[2018,1,26]]}},"alternative-id":["10.1515\/cclm-2017-0264"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2017-0264","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"type":"electronic","value":"1437-4331"},{"type":"print","value":"1434-6621"}],"subject":[],"published":{"date-parts":[[2017,8,29]]}}}